Publication | Closed Access

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

OncologyFive-year SurvivalPhase Iii ImbrellaCancer ManagementPathologyExtension StudyCancer TreatmentMedicineRadiation OncologyLung Cancer